CARDIOONCOLOGY: CHEMOTHERAPY DRUGS AND RADIATION THERAPY IMPACT ON CARDIOVASCULAR SYSTEM

Cover Page

Cite item

Full Text

Abstract

Anticancer therapy can cause angina pectoris, acute coronary syndrome, stroke, critical limb ischemia, arterial hypertension, arrhythmias and heart failure. The new specialization in cardiology, called cardiooncology, exploring the complications of cardiovascular system, arising during the treatment of cancer. The first part of the review, based on the publications of the last decades, is dedicated to the definition of cardiooncology, mechanisms of cardiac and vascular toxicity with a number of anticancer drugs affecting the cardiovascular system.

About the authors

D P Doundoua

Федеральный научно-клинический центр специализированных видов медицинской помощи и медицинских технологий ФМБА России

Email: cardio@fnkc-fmba.ru
д.м.н., руководитель кардиологического центра Москва,Ореховый бульвар,28

A V Staferov

Федеральный научно-клинический центр специализированных видов медицинской помощи и медицинских технологий ФМБА России

к.м.н. заведующий отделением рентгенохирургических методов диагностики и лечения Москва,Ореховый бульвар,28

A V Sorokin

Федеральный научно-клинический центр специализированных видов медицинской помощи и медицинских технологий ФМБА России

сотрудник отделения рентгенохирургических методов диагностики и лечения Москва,Ореховый бульвар,28

A G Kedrova

Федеральный научно-клинический центр специализированных видов медицинской помощи и медицинских технологий ФМБА России

Email: kedrova.anna@gmail.com
д.м.н., профессор, заведующая отделением онкологии Москва,Ореховый бульвар,28

References

  1. Cancer Data and Statistics. 2011. http://www.cdc. gov/cancer/dcpc/data/. Accessed on 10 June 2015.
  2. Herrmann J, Lerman A. An update on cardio-oncology. Trends Cardiovasc Med 2014;24:285-295.
  3. Zamorano JL, et al. 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology. Eur Heart J. 2016 Sep 21;37(36):2768-2801.
  4. Iliescu C, et al. SCAI Expert Consensus Statement: Evaluation, Management, and Special Considerations of Cardio-Oncology Patients in the Cardiac Catheterization Laboratory. Catheter Cardiovasc Interv 2016; Apr;87(5):E202-23. doi: 10.1002/ccd.26379.
  5. Plana JC, et al. Expert Consensus for Multimodality Imaging Evaluation of Adult Patients during and after Cancer Therapy: A Report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr 2014;27:911-39.
  6. Alexander J, Dainiak N, Berger HJ, et al. Serial assessment of doxorubicin cardiotoxicity with quantitative radionuclide angiocardiography. N Engl J Med. 1979;300(6 ):278-83.
  7. Buzdar AU, Marcus C, Smith TL, et al. Early and delayed clinical cardiotoxicity of doxorubicin. Cancer.1985;55(12 ):2761-5.
  8. Suter TM, Ewer M S. Cancer drugs and the heart: importance and management. Euro Heart J. 2013; 34:1102-1111.
  9. Perez EA, Romond EH, Suman VJ, Jeong JH, et al. Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: joint analysis of data from NCCTG N9831 and NSABP B-31. J Clin Oncol 2011;29:3366-3373.
  10. Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 2010;376:687-697.
  11. Kerkela R, Grazette L, Yacobi R, Iliescu C, et al. Cardiotoxicity of the cancer therapeutic agent imatinib mesylate. Nat Med 2006;12:908-916.
  12. Atallah E, Durand JB, Kantarjian H, Cortes J. Congestive heart failure is a rare event in patients receiving imatinib therapy. Blood 2007;110:1233-1237.
  13. Stefenelli T, Kuzmits R, Ulrich W, Glogar D. Acute vascular toxicity after combination chemotherapy with cisplatin, vinblastine, and bleomycin for testicular cancer. Eur Heart J 1988;9:552-556.
  14. Samuels BL, Vogelzang NJ, Kennedy BJ. Severe vascular toxicity associated with vinblastine, bleomycin, and cisplatin chemotherapy. Cancer Chemother Pharmacol 1987;19:253-256.
  15. Gianni M, Dentali F, Lonn E. 5 flourouracil-induced apical ballooning syndrome: A case report. Blood Coagul Fibrinolysis 2009;20:306-308.
  16. Sudhoff T, Enderle MD, Pahlke M, et al. 5-Fluorouracil induces arterial vasocontractions. Ann Oncol 2004;15:661-664.
  17. Polk A, Vaage-Nilsen M, Vistisen K, Nielsen DL. Cardiotoxicity in cancer patients treated with 5-fluorouracil or capecitabine: A systematic review of incidence, manifestations and predisposing factors. Cancer Treat Rev 2013 Dec; 39(8):974-84. doi: 10.1016/j.ctrv.2013.03.005.
  18. Stewart T, Pavlakis N, Ward M. Cardiotoxicity with 5-fluorouracil and capecitabine: More than just vasospastic angina. Intern Med J 2010;40:303-307.
  19. Ambrosy AP, Kunz PL, Fisher GA, Witteles RM. Capecitabine induced chest pain relieved by diltiazem. Am J Cardiol 2012; 110:1623-1626.
  20. Schrader C, Keussen C, Bewig B, von Freier A, Lins M. Symptoms and signs of an acute myocardial ischemia caused by chemotherapy with Paclitaxel (Taxol) in a patient with metastatic ovarian carcinoma. Eur J Med Res 2005;10:498-501.
  21. Berliner S, Rahima M, Sidi Y, et al. Acute coronary events following cisplatin-based chemotherapy. Cancer Invest 1990;8:583-586.
  22. Jafri M, Protheroe A. Cisplatin-associated thrombosis. Anticancer Drugs 2008;19:927-929.
  23. Karabay KO, Yildiz O, Aytekin V. Multiple coronary thrombi with cisplatin. J Invasive Cardiol 2014;26:E18-E20.
  24. Schwarzer S, Eber B, Greinix H, Lind P. Non-Q-wave myocardial infarction associated with bleomycin and etoposide chemotherapy. Eur Heart J 1991;12:748- 750.
  25. Chen XL, Lei YH, Liu CF, et al. Angiogenesis inhibitor bevacizumab increases the risk of ischemic heart disease associated with chemotherapy: A meta-analysis. PLoS One 2013;8:e66721.
  26. Scappaticci FA, Skillings JR, Holden SN, et al. Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab. J Natl Cancer Inst 2007; 99:1232-1239.
  27. Schutz FA, Je Y, Azzi GR, Nguyen PL, Choueiri TK. Bevacizumab increases the risk of arterial ischemia: A large study in cancer patients with a focus on different subgroup outcomes. Ann Oncol 2011;22:1404-1412.
  28. Sen F, Yildiz I, Basaran M, et al. Impaired coronary flow reserve in metastatic cancer patients treated with sunitinib. J Buon 2013;18:775-781.
  29. Kappers MH, van Esch JH, Sluiter W, et al. Hypertension induced by the tyrosine kinase inhibitor sunitinib is associated with increased circulating endothelin-1 levels. Hypertension 2010;56:675-681.
  30. Kappers MH, de Beer VJ, Zhou Z, et al. Sunitinib-induced systemic vasoconstriction in swine is endothelin mediated and does not involve nitric oxide or oxidative stress. Hypertension 2012;59:151-157.
  31. Arima Y, Oshima S, Noda K, et al. Sorafenib-induced acute myocardial infarction due to coronary artery spasm. J Cardiol 2009;54:512-515.
  32. Porto I, Leo A, Miele L, et al. A case of variant angina in a patient under chronic treatment with sorafenib. Nat Rev Clin Oncol 2010;7:476-480.
  33. Naib T, Steingart RM, Chen CL. Sorafenib-associated multivessel coronary artery vasospasm. Herz 2011;36:348-351.
  34. Holm PW, Slart RH, Zeebregts CJ, Hillebrands JL, Tio RA. Atherosclerotic plaque development and instability: A dual role for VEGF. Ann Med 2009;41:257- 264.
  35. Duran JM, Makarewich CA, Trappanese D, et al. Sorafenib cardiotoxicity increases mortality after myocardial infarction. Circ Res 2014;114:1700-1712.
  36. Di Lorenzo G, Autorino R, Bruni G, et al. Cardiovascular toxicity following sunitinib therapy in metastatic renal cell carcinoma: A multicenter analysis. Ann Oncol 2009;20:1535-1542.
  37. Aichberger KJ, Herndlhofer S, Schernthaner GH, et al. Progressive peripheral arterial occlusive disease and other vascular events during nilotinib therapy in CML. Am J Hematol 2011;86:533-539.
  38. Quintas-Cardama A, Kantarjian H, Cortes J. Nilotinib-associated vascular events. Clin Lymphoma Myeloma Leuk 2012;12:337-340.
  39. Arunprasath P, Gobu P, Dubashi B, Satheesh S, Balachander J. Rituximab induced myocardial infarction: A fatal drug reaction. J Cancer Res Ther 2011;7:346-348.
  40. Togna GI, Togna AR, Franconi M, Caprino L. Cisplatin triggers platelet activation. Thromb Res. 2000;99:503-509.
  41. Dieckmann KP, Gerl A, Witt J, Hartmann JT. Myocardial infarction and other major vascular events during chemotherapy for testicular cancer. Ann Oncol 2010;21:1607-1611.
  42. Parekh A, Chen MH, Graham P, et al. Role of androgen deprivation therapy in early salvage radiation among patients with prostate-specific antigen level of 0.5 or less. Clin Genitourin Cancer 2015 Feb;13 (1):e1-6.
  43. Ziehr DR, Chen MH, Zhang D, et al. Association of androgen deprivation therapy with excess cardiac-specific mortality in men with prostate cancer. BJU Int 2014;116:358-365.
  44. Carles Galceran J, Bastus Piulats R, Martin-Broto J, et al. A phase II study of vinorelbine and estramustine in patients with hormone resistant prostate cancer. Clin Transl Oncol 2005;7:66-73.
  45. Nakagami Y, Ohori M, Sakamoto N, et al. Safety and efficacy of docetaxel, estramustine phosphate and hydrocortisone in hormone-refractory prostate cancer patients. Int J Urol 2010;17: 629-634.
  46. Lubiniecki GM, Berlin JA, Weinstein RB, Vaughn DJ. Thromboembolic events with estramustine phosphate-based chemotherapy in patients with hormone-refractory prostate carcinoma: Results of a meta-analysis. Cancer 2004;101:2755-2759.
  47. Albertsen PC, Klotz L, Tombal B, et al. Cardiovascular morbidity associated with gonadotropin releasing hormone agonists and an antagonist. Eur Urol 2014; 65:565-573.
  48. van Werkum JW, Heestermans AA, Zomer AC, et al. Predictors of coronary stent thrombosis: The Dutch Stent Thrombosis Registry. J Am Coll Cardiol 2009;53:1399-1409.
  49. Cahill TJ, Chowdhury O, Myerson SG, et al. Myocardial infarction with intracardiac thrombosis as the presentation of acute promyelocytic leukemia: Diagnosis and follow-up by cardiac magnetic resonance imaging. Circulation 2011;123:e370-e372.
  50. Sargsyan Z, Higgins C, Alexandrescu S, Ott DA, Jain SK. Acute promyelocytic leukemia as a cause of intracoronary drug-eluting stent thrombosis. Tex Heart Inst J 2012;39:416-419.
  51. Kupeli S, Hazirolan T, Varan A, et al. Evaluation of coronary artery disease by computed tomography angiography in patients treated for childhood Hodgkin’s lymphoma. J Clin Oncol 2010;28:1025-1030.
  52. Taylor CW, Nisbet A, McGale P, Darby SC. Cardiac exposures in breast cancer radiotherapy: 1950s-1990s. Int J Radiat Oncol Biol Phys 2007;69:1484-1495.
  53. Correa CR, Litt HI, Hwang WT, et al. Coronary artery findings after left-sided compared with right-sided radiation treatment for early-stage breast cancer. J Clin Oncol 2007;25:3031-3037.
  54. Darby S, McGale P, Correa C, et al. Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: Meta-analysis of individual patient data for 10,801 women in 17 randomized trials. Lancet 2011;378:1707-1716.
  55. Mulrooney DA, Yeazel MW, Kawashima T, et al. Cardiac outcomes in a cohort of adult survivors of childhood and adolescent cancer: Retrospective analysis of the Childhood Cancer Survivor Study cohort. BMJ 2009;339:b4606.
  56. Lee CC, Su YC, Ho HC, et al. Increased risk of ischemic stroke in young nasopharyngeal carcinoma patients. Int J Radiat Oncol Biol Phys 2011;81:e833-e838.
  57. Lam WW, Leung SF, So NM, et al. Incidence of carotid stenosis in nasopharyngeal carcinoma patients after radiotherapy. Cancer 2001;92:2357-2363.
  58. Dorresteijn LD, Kappelle AC, Boogerd W, et al. Increased risk of ischemic stroke after radiotherapy on the neck in patients younger than 60 years. J Clin Oncol 2002;20:282-288.
  59. Cheng SW, Ting AC, Lam LK, Wei WI. Carotid stenosis after radiotherapy for nasopharyngeal carcinoma. Arch Otolaryngol Head Neck Surg 2000;126:517-521.
  60. Al-Mubarak N, Roubin GS, Iyer SS, et al. Carotid stenting for severe radiation-induced extracranial carotid artery occlusive disease. J Endovasc Ther 2000;7:36-40.
  61. Ting AC, Cheng SW, Yeung KM, et al. Carotid stenting for radiation-induced extracranial carotid artery occlusive disease: Efficacy and midterm outcomes. J Endovasc Ther 2004;11:53-59.
  62. Houdart E, Mounayer C, Chapot R, Saint-Maurice JP, Merland JJ. Carotid stenting for radiation-induced stenoses: A report of 7 cases. Stroke 2001;32:118-121.
  63. Hull MC, Morris CG, Pepine CJ, Mendenhall NP. Valvular dysfunction and carotid, subclavian, and coronary artery disease in survivors of Hodgkin lymphoma treated with radiation therapy.JAMA 2003;290:2831-2837.
  64. De Bruin ML, Dorresteijn LD, van’t Veer MB, et al. Increased risk of stroke and transient ischemic attack in 5-year survivors of Hodgkin lymphoma. J Natl Cancer Inst 2009;101:928-937.
  65. Milutinovic J, Darcy M, Thompson KA. Radiation-induced renovascular hypertension successfully treated with transluminal angioplasty: Case report. Cardiovasc Intervent Radiol 1990;13:29-31.
  66. Saka B, Bilge AK, Umman B, et al. Bilateral renal artery stenosis after abdominal radiotherapy for Hodgkin’s disease. Int J Clin Pract 2003;57:247-248.
  67. Jurado JA, Bashir R, Burket MW. Radiation- induced peripheral artery disease. Catheter Cardiovasc Interv 2008;72:563-568.
  68. Saliou C, Julia P, Feito B, Renaudin JM, Fabiani JN. Radiation-induced arterial disease of the lower limb. Ann Vasc Surg 1997;11:173-177.

Copyright (c) 2016 Doundoua D.P., Staferov A.V., Sorokin A.V., Kedrova A.G.

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies